|
Jul 22
|
20 Countries With The Highest Rate Of Diabetes
|
|
Jul 21
|
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
|
|
Jul 20
|
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
|
|
Jul 18
|
Sanofi: Information concerning the total number of voting rights and shares – June 2023
|
|
Jul 18
|
Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants
|
|
Jul 18
|
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
|
|
Jul 17
|
FDA Approves First RSV Drug to Protect All Infants From Virus
|
|
Jul 17
|
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
|
|
May 1
|
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
|
|
May 1
|
Sanofi/Provention: innovative diabetes drug is a good fit
|
|
May 1
|
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
|
|
Apr 30
|
BioNTech/Pfizer’s mooted EU deal for 70mn Covid shots threatens rivals
|
|
Apr 30
|
27 Largest Biotech Companies in the US
|
|
Apr 28
|
Sanofi (SNY) Q1 2023 Earnings Call Transcript
|
|
Apr 27
|
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
|
|
Apr 27
|
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
|
|
Apr 27
|
Customized Treatments in Modern Medicine: Hear from Thirty Madison President and CFO Live from the NYSE Floor
|
|
Apr 27
|
Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
|
|
Apr 27
|
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
|
|
Apr 27
|
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
|